| Patent application number | Description | Published |
|---|
| 20080249260 | Methods of preparing polymers having terminal amine groups - The present invention is directed to methods of preparing linear polymers such as polyalkylene oxides containing a terminal amine in high purity. One preferred method includes reacting a polyalkylene oxide such as polyethylene glycol containing a terminal azide with a phosphine-based reducing agent such as triphenylphosphine or an alkali metal borohydride reducing agent such as sodium borohydride in a solvent to reflux. The resultant polymer-amines are of sufficient purity so that expensive and time consuming purification steps required for pharmaceutical grade polymers are avoided. | 10-09-2008 |
| 20080305070 | RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS - Activated polymeric bicine derivatives such as, | 12-11-2008 |
| 20090016985 | POLYMERIC DRUG DELIVERY SYSTEM CONTAINING A MULTI-SUBSTITUTED AROMATIC MOIETY - The present invention provides polymeric delivery systems including a multi-substituted aromatic moiety. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed. | 01-15-2009 |
| 20090017004 | POLYMERIC DRUG DELIVERY SYSTEMS CONTAINING AN AROMATIC ALLYLIC ACID - The present invention provides polymeric delivery systems including an aromatic allyllic acyl group. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed. | 01-15-2009 |
| 20090074706 | MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN FOR TREATMENT OF BREAST, COLORECTAL, PANCREATIC, OVARIAN AND LUNG CANCERS - A four arm-polyethylene glycol-7-ethyl-10-hydroxycamptothecin conjugate, such as, | 03-19-2009 |
| 20090156629 | INDENOISOQUINOLINE-RELEASABLE POLYMER CONJUGATES - The present invention provides releasably-linked indenoisoquinoline polymer conjugates. Methods of making the conjugates and methods of treating mammals using the same are also disclosed. | 06-18-2009 |
| 20090202573 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES - The present invention provides polymeric conjugates containing positively charged moieties. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed. | 08-13-2009 |
| 20090203706 | LYSINE-BASED POLYMERIC LINKERS - The present invention provides polymeric linkers containing branching moieties. Methods of making the polymeric linkers and methods of making conjugates using the same are also disclosed. | 08-13-2009 |
| 20090221471 | PRODRUGS OF VANCOMYCIN WITH HYDROLYSIS RESISTANT POLYMER LINKAGES - Vancomycin-polymer conjugates are disclosed. In preferred aspects, polymer residues which are hydrolysis resistant in vitro, are selectively attached to the sugar amino and/or N-methyl amino groups of vancomycin and related compounds. Vancomycin-polymer conjugates made by the methods and methods of treatment using the conjugates are also disclosed. | 09-03-2009 |
| 20090232833 | POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS - The present invention provides polymeric delivery systems including hindered ester moieties. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed. | 09-17-2009 |
| 20090318538 | POLYMERIC OLIGONUCLEOTIDE PRODRUGS - Polymer conjugates containing nucleotides and/or oligonucleotides are disclosed. | 12-24-2009 |
| 20100056543 | POSACONAZOLE POLYMER CONJUGATES AND METHODS OF TREATMENT USING POSACONAZOLE AND POLYMER CONJUGATES THEREOF - Improved posaconazole-based compositions and methods of treating and preventing fungal infections, cancer or metastatic diseases are disclosed. In preferred aspects, the conjugates are PEG-posaconazole conjugates in which the PEG has a molecular weight of about 20,000 daltons. | 03-04-2010 |
| 20100203066 | POLYMERIC LINKERS CONTAINING PYRIDYL DISULFIDE MOIETIES - The present invention provides polymeric linkers containing pyridyl disulfide moieties. Methods of making the polymeric linkers and methods of making conjugates using the same are also disclosed. | 08-12-2010 |
| 20100204261 | MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN FOR TREATMENT OF BREAST, COLORECTAL, PANCREATIC, OVARIAN AND LUNG CANCERS - A four arm-polyethylene glycol-7-ethyl-10-hydroxycamptothecin conjugate, such as, | 08-12-2010 |
| 20100233190 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS - The present invention provides single chain antibody-directed polymeric prodrugs containing multifunctional linkers. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed. | 09-16-2010 |
| 20100234444 | HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY - The invention provides hindered ester-based biodegradable linkers for the delivery of oligonucleotides in vivo, as well as method of making and using the same. | 09-16-2010 |
| 20100279408 | POLYMERIC SHORT INTERFERING RNA CONJUGATES - The present invention provides polymeric siRNA conjugates. Methods for down-regulation of gene expression in vivo and in vitro and for inhibition of the growth of cancer cells using the conjugates are also disclosed. | 11-04-2010 |
| 20110105413 | POLYMERIC SYSTEMS CONTAINING INTRACELLULAR RELEASABLE DISULFIDE LINKER FOR THE DELIVERY OF OLIGONUCLEOTIDES - The present invention provides polymeric prodrugs including an intracellular releasable disulfide linker for the delivery of oligonucleotides. Methods of making the compounds as well as methods of delivering nucleic acids to tumor cells in a mammal using the same are also provided. | 05-05-2011 |
| 20110111044 | NANOPARTICLE COMPOSITIONS FOR NUCLEIC ACIDS DELIVERY SYSTEM - The present invention is directed to nanoparticle compositions for the delivery of oligonucleotides and methods of modulating an expression of a targeted gene using the nanoparticle compositions. In particular, the invention relates to oligonucleotides encapsulated in a mixture of a cationic lipid, a fusogenic lipid and a PEG lipid. | 05-12-2011 |
